![Mitchell Shirvan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mitchell Shirvan
Chief Executive Officer at
D.H.S Medical Ltd.
Net worth: 16 523 $ as of 2026-07-30
Profile
Mitchell Shirvan currently works at D.H.S Medical Ltd., as Chief Executive Officer, Silexion Therapeutics Corp., as Chief Scientific & Development Officer from 2024, and Silexion Therapeutics Ltd., as Chief Scientific & Development Officer from 2022.
Dr. Shirvan also formerly worked at Macrocure Ltd., as Chief Executive Officer from 2008 to 2012, Teva Pharmaceutical Industries Ltd., as Senior Director-Global Strategic Business from 1992 to 2008, and VYNE Pharmaceuticals Ltd., as Vice President-Innovation & Discovery from 2017 to 2019.
Dr. Shirvan received his Masters Business Admin degree from the University of Bradford and doctorate degree from The Hebrew University of Jerusalem.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
2.1% | 2026-06-10 | 8,789 ( 2.1% ) | 16 523 $ | 2026-07-30 |
Mitchell Shirvan active positions
| Companies | Position | Start |
|---|---|---|
D.H.S Medical Ltd.
 D.H.S Medical Ltd. Packaged SoftwareTechnology Services Develops a platform technology for treating and monitoring heart failure | Chief Executive Officer | - |
Silexion Therapeutics Ltd.
 Silexion Therapeutics Ltd. BiotechnologyHealth Technology Operates as aa clinical-stage oncology-focused biotechnology company | Chief Tech/Sci/R&D Officer | 2022-03-31 |
Former positions of Mitchell Shirvan
| Companies | Position | End |
|---|---|---|
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for dermatology, gynecology, wounds and burns and ophthalmic disorders | Chief Tech/Sci/R&D Officer | 2017-07-31 |
| MACROCURE LTD | Chief Executive Officer | 2011-12-31 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 2007-12-31 |
Training of Mitchell Shirvan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for dermatology, gynecology, wounds and burns and ophthalmic disorders | Health Technology |
University of Bradford
 University of Bradford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Macrocure Ltd.
 Macrocure Ltd. Medical SpecialtiesHealth Technology Develops a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers | Health Technology |
D.H.S Medical Ltd.
D.H.S Medical Ltd. Packaged SoftwareTechnology Services Develops a platform technology for treating and monitoring heart failure | Technology Services |
Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. BiotechnologyHealth Technology Operates as aa clinical-stage oncology-focused biotechnology company | Health Technology |
- Stock Market
- Insiders
- Mitchell Shirvan
